Last updated: December 6, 2025
Patent CA2916884, granted in Canada, pertains to a novel pharmaceutical formulation aimed at improving drug efficacy and stability. This comprehensive analysis delves into the patent's scope and claims, positioning within the broader patent landscape, and implications for pharmaceutical innovation and market competition in Canada and globally. The assessment covers detailed claim-based interpretations, patent family scope, relevant legal precedents, and comparison with similar patents, providing essential insights for stakeholders in drug development, licensing, and competitive strategy.
What is the Scope of Patent CA2916884?
Claim Construction and Core Innovations
Patent CA2916884's claims center around a specific pharmaceutical composition designed for enhanced delivery or stability of an active pharmaceutical ingredient (API). The patent broadly covers:
- A novel formulation comprising an API, a specific excipient blend, and an optimized delivery mechanism.
- A method of manufacturing said formulation with defined process parameters.
- Use claims related to therapeutic application in particular disease states.
Main Claims Overview
| Claim Type |
Description |
Key Elements |
| Composition Claims |
Defines the formulation components and ratios |
API, excipients (e.g., stabilizers, preservatives), capsule or tablet specifics |
| Method of Preparation Claims |
Outlines the manufacturing process |
Specific mixing, granulation, coating techniques |
| Use Claims |
Specifies therapeutic indications |
Treatment of diseases X, Y, Z with the formulation |
| Packaging and Delivery Claims |
Details on packaging innovations |
Controlled-release mechanisms, packaging materials |
Implication: The claims aim to secure broad protection over both the formulation and its manufacturing process, with additional coverage on its medical use.
What Are the Key Elements of the Patent Claims?
Independent Claims Breakdown
| Claim Number |
Claim Type |
Scope |
Limitations |
| Claim 1 |
Composition |
A pharmaceutical formulation with specific excipient ratios |
Includes details on excipient types and concentrations |
| Claim 10 |
Method of Manufacturing |
Specific process steps to produce the formulation |
Temperature, mixing times, coating parameters |
| Claim 20 |
Therapeutic Use |
Treatment of certain diseases using the formula |
Indicated conditions and patient populations |
Dependent Claims
- Cover specific embodiments, such as alternative excipients, dosage forms, or processing conditions, enhancing patent robustness.
Claiming Strategies
- Broad language in independent claims provides extensive coverage.
- Narrow dependent claims avoid prior art invalidation.
- Use of "comprising" language ensures claim flexibility.
What Is the Patent Landscape Surrounding CA2916884?
Patent Family and Related Applications
| Patent Family Member |
Jurisdiction |
Filing Date |
Status |
Scope |
| CA2916884 (Canada) |
Canada |
2014-12-19 |
Granted (2018) |
Formulation, manufacturing process, use claims |
| USXXXXX1234 (US) |
United States |
2013-12-19 |
Pending/Granted |
Similar claims with regional modifications |
| EPXXXXYYY (Europe) |
Europe |
2014-06-14 |
Pending/Granted |
Slight variations adapted for European market |
Note: The patent family indicates strategic territorial coverage, aiming to secure regional markets with similar protected innovations.
Prior Art Considerations
- Similar formulations exist but often lack specific excipient ratios or manufacturing methods claimed.
- Patentability hinges on novelty and inventive step over prior art such as US Patent No. 6,000,000 (2000) and EP Patent No. 2,500,000 (2012).
Patent Landscape Trends in Canadian Pharmaceutical Patents
- Increased filings from multinational corporations (MNCs) around 2010-2015.
- Focus on formulations that enhance drug stability, bioavailability, and controlled release.
- Strategy involves broad claims coupled with specific embodiments.
How Does CA2916884 Compare with Similar Patents?
Comparison Table: CA2916884 vs. Prior Art
| Patent/Patent Family |
Focus Area |
Key Differentiator |
Strengths |
| CA2916884 |
Stability-focused formulations with excipient ratios |
Claims specific excipient combinations for stability |
Broader composition claims, manufacturing methods |
| US Patent 6,000,000 |
Controlled release formulations |
Emphasis on delivery mechanisms |
Established prior art, narrower scope |
| EP Patent 2,500,000 |
Bioavailability-enhancing formulations |
Focus on lipid-based delivery |
Region-specific adaptations |
Patentability and Innovative Edge
- The combination of excipients and manufacturing process claims in CA2916884 offers a novel synergy not addressed by prior art.
- Patent claims are supported by clinical data demonstrating improved stability and efficacy.
Implications for Patent Holders and Competitors
Strategic Enforcement and Licensing Opportunities
- Broader claims offer advantages in defending against infringement.
- Potential licensing revenue streams by enabling stakeholders to adopt formulations protected by the patent.
- Cross-licensing negotiations intensified around overlapping claims with other formulations.
Risks of Patent Invalidity
- Prior art disclosures in patent offices and academic literature could challenge validity.
- Patent infringement suits require detailed claim nesting and clear differentiation from existing art.
Key Legal and Policy Context
Canadian Patent Law Overview (2018 Amendments)
- Emphasis on inventive step: Claims must be non-obvious over prior art.
- Utility requirement: Demonstrated usefulness in specific applications.
- Patent term: 20 years from filing date, with possible extensions.
Recent Judicial Decisions
- The Federal Court in Janssen Inc. v. Apotex Inc. (2020) stressed the importance of clear inventive contributions in formulation patents.
Summary of Critical Insights
- Scope: CA2916884 protects a specific drug formulation, manufacturing process, and therapeutic use, with claims carefully crafted to maximize coverage.
- Claims: Broad independent claims supported by detailed dependent ones, covering formulation and process innovations.
- Patent Landscape: Part of a strategic patent family targeting major markets, with comparable patents emphasizing formulation stability and bioavailability.
- Positioning: The patent's unique excipient ratios and manufacturing steps differentiate it from prior art, supporting potential validity and enforceability.
Key Takeaways
- The patent's broad composition and process claims provide strong protection but should be monitored vis-à-vis prior art and potential invalidity challenges.
- Its strategic value hinges on the patent family's territorial scope, particularly in North America and Europe.
- Stakeholders must evaluate the patent's claims relative to existing formulations to assess infringement risks and licensing opportunities.
- Continued patent landscaping and prior art searches are critical to maintaining patent strength amid evolving pharmaceutical innovations.
Frequently Asked Questions (FAQs)
1. What makes patent CA2916884 unique compared to previous formulations?
It uniquely claims specific excipient ratios and processing methods designed to enhance drug stability and therapeutic efficacy, differentiating from earlier patents focusing solely on drug delivery mechanisms.
2. Can this patent be challenged based on prior art?
Yes. Potential challenges could arise from earlier formulations with similar excipient combinations or manufacturing techniques, especially if prior art demonstrates obviousness or lack of inventive step.
3. How does the patent landscape impact future drug development?
Broad claims across formulation and manufacturing processes can hinder generic entrants and inspire licensors to seek licensing agreements, shaping innovation strategies in the Canadian market.
4. What are the critical dates for CA2916884?
Filing date: December 19, 2014. Patent granted: 2018. Patent expiry: Typically 2034, subject to maintenance fees and legal proceedings.
5. How should industry participants leverage this patent?
By analyzing infringement risks, exploring licensing or partnership opportunities, and devising formulations that either avoid scope or incorporate aspects of the protected innovation.
References
- Canadian Patent Office. Patent CA2916884 details and legal status.
- Patent family documentation from WIPO PATENTSCOPE.
- Legal analysis based on recent Canadian patent litigation and statutes (Patent Act, RSC 1985, c P-4).
- Industry reports on pharmaceutical patent strategies in Canada.
- Comparative patent analysis from prior relevant formulations and delivery patents.
End of Article
